Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8651426 | 0.88 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10586178 | 0.88 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10345916 | 0.83 | ADORA1 (0.61) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3300186 | 0.82 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL5024895 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL12963362 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7803298 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL481524 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10997946 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2040670 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20080009623-A1 | Pyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-10 | — | — | US | disclosed |
| EP-1439176-B1 | PYRIMIDONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-7189717-B2 | Medicinal compositions promoting bowel movement | EISAI CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | disclosed |
| US-7160892-B2 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1439176-A1 | PYRIMIDONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6579868-B1 | Reacting a 2,6-dihalo-substituted purine compound with ammonia or an amine | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| EP-1054012-B1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | EISAI CO LTD (JP) | 2003-06-11 | — | — | EP | disclosed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1300147-A1 | Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus | Eisai Co. Ltd (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-1283056-A1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | Eisai Co., Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1054012-A1 | PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES | Eisai Co., Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885SMN1; SMN2 1521/4885ADORA3 4/4885 |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA1 328/4885SMN1; SMN2 3141/4885ADORA3 129/4885 |
| US-20080009623-A1 | Pyrimidine compounds | DPYD, TYMP, UMPS | ADORA1 689/4885SMN1; SMN2 1548/4885ADORA3 1299/4885 |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | ADORA1 1/4885SMN1; SMN2 4309/4885ADORA3 4/4885 |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | ADORA2A, ADORA3, ADORA2B | ADORA1 4/4885SMN1; SMN2 2926/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.